Longitudinal cohort study; measurements before start of systemic therapy and one year later.
Aged 18-39 years at cancer diagnosis
Having a histologically and/or cytologically confirmed cancer diagnosis, including leukemia, (non-)Hodgkin lymphoma, testicular cancer, osteosarcoma, Ewing sarcoma, breast cancer, and cervical cancer.
Scheduled to start systemic therapy with curative intent. Allowed treatments (concurrent or sequential) are: surgery, radiotherapy, chemotherapy, antibodies.
patients who are not able to understand the patient information letter and informed consent form
patients who will be treated with immune checkpoint inhibitors or targeted therapy with inhibitors of angiogenesis
patients who have been treated with systemic therapy or radiotherapy for a previous malignancy (exceptions: in situ carcinoma of the cervix or uterus and adequately treated basal and squamous cell carcinoma of the skin).
AYA patients who will start systemic treatment at the Department of Medical Oncology or Haematology of the University Medical Center Groningen are potential study participants. Patients will be informed about the study during a regular visit to the outpatient clinic or during their admission to the nursing ward. From the moment the study starts, the investigators aim to include all consecutive patients during a period of 2 years.
Cohort
Prospective
Blood sampling
Procedure/SurgeryStudy measurements will be performed twice and consist of blood withdrawal and physical examination (weight, height, waist-hip ratio, and blood pressure).
Change in senescence marker P16
determine change in senescence marker P16 between start of systemic therapy and one year later.
Changes in SASPs and vascular markers
Determine changes in SASPs and vascular markers
Prevalence of classical cardiovascular risk factors (smoking, lipids, BMI, glucose)
Determine prevalence of classical cardiovascular risk factors (lipids, BMI, glucose)
Association between treatment type and change in senescence marker P16
Determine association between treatment type and change in senescence marker P16
Association between age and change in senescence marker P16
Determine association between age and change in senescence marker P16
Click on the lead sponsor to view all of their trials.
University Medical Center Groningen
Lead sponsor
UMCG Kanker Researchfonds
Collaborator
